z-logo
Premium
Lack of Association of OPRM1 and ABCB1 Single‐Nucleotide Polymorphisms to Oxycodone Response in Postoperative Pain
Author(s) -
Zwisler Stine T.,
Enggaard Thomas P.,
Mikkelsen Soeren,
Verstuyft Céline,
Becquemont Laurent,
Sindrup Soeren H.,
Brosen Kim
Publication year - 2012
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1177/0091270010397729
Subject(s) - analgesic , oxycodone , single nucleotide polymorphism , medicine , anesthesia , allele , genotype , opioid , genetics , biology , gene , receptor
Purpose: The aim of the study was to search for an association between the single‐nucleotide polymorphisms A118G in OPRM1 and C3435T and G2677T/A in ABCB1 and the analgesic effect of intravenous oxycodone in postoperative pain. Methods: There were 268 patients with postoperative pain after, primarily, thyroidectomy. At given times during the first 24 hours postoperatively, their pain was rated at rest and during activity according to a numeric rating scale (0 = no pain, 10 = worst possible pain) and calculated as pain time area under the curve 0–24 hours . A negative answer in a final questionnaire and/or the use of rescue medication categorized a patient as a nonresponder. Results: For OPRM1, there was no difference found between the wild type and the variant allele in the percentages of nonresponders (118AA = 16.4% vs 118AG/118GG = 17.0%, P = 1.0) or in the pain ratings. For ABCB1, no difference was found between the wild type and the variant alleles for single‐nucleotide polymorphism tested as percentages of nonresponders (3435CC = 17.5% vs 3435CT/3435TT = 15.8%, P = .85; 2677GG = 17.8% vs 2677GT/2677TT = 15.8%, P = .74) or pain ratings. Conclusion: No association was found between the tested single‐nucleotide polymorphisms in OPRM1 and ABCB1 and changes in the analgesic effect of oxycodone.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here